Schering Acquires Levitra Rights From Bayer; Vytorin Launch Is Still Priority

Schering-Plough's acquisition of Bayer's primary care products in the U.S. will not distract the company from the launch of Vytorin, Schering CEO Fred Hassan told investors Sept. 13 at a Bear Stearns conference in New York

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet